These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20704261)

  • 1. Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.
    Rutkoski TJ; Kink JA; Strong LE; Schilling CI; Raines RT
    Bioconjug Chem; 2010 Sep; 21(9):1691-702. PubMed ID: 20704261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity of bovine seminal ribonuclease: monomer versus dimer.
    Lee JE; Raines RT
    Biochemistry; 2005 Dec; 44(48):15760-7. PubMed ID: 16313179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity.
    Rutkoski TJ; Kink JA; Strong LE; Raines RT
    Cancer Biol Ther; 2011 Aug; 12(3):208-14. PubMed ID: 21633186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A ribonuclease inhibitor resistant dimer of human pancreatic ribonuclease displays specific antitumor activity.
    Attery A; Dey P; Tripathi P; Batra JK
    Int J Biol Macromol; 2018 Feb; 107(Pt B):1965-1970. PubMed ID: 29042278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing an inhibitor unleashes a cytotoxic enzyme.
    Dickson KA; Raines RT
    Biochemistry; 2009 Jun; 48(23):5051-3. PubMed ID: 19402708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonuclease A variants with potent cytotoxic activity.
    Leland PA; Schultz LW; Kim BM; Raines RT
    Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10407-12. PubMed ID: 9724716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of potent cytotoxic ribonucleases by cationization: enhanced cellular uptake and decreased interaction with ribonuclease inhibitor by chemical modification of carboxyl groups.
    Futami J; Maeda T; Kitazoe M; Nukui E; Tada H; Seno M; Kosaka M; Yamada H
    Biochemistry; 2001 Jun; 40(25):7518-24. PubMed ID: 11412105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein.
    Johnson RJ; McCoy JG; Bingman CA; Phillips GN; Raines RT
    J Mol Biol; 2007 Apr; 368(2):434-49. PubMed ID: 17350650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. Generation of inhibitor-resistant cytotoxic variants.
    Gaur D; Swaminathan S; Batra JK
    J Biol Chem; 2001 Jul; 276(27):24978-84. PubMed ID: 11342552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
    Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
    J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level soluble production and characterization of porcine ribonuclease inhibitor.
    Klink TA; Vicentini AM; Hofsteenge J; Raines RT
    Protein Expr Purif; 2001 Jul; 22(2):174-9. PubMed ID: 11437592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribonuclease inhibitor regulates neovascularization by human angiogenin.
    Dickson KA; Kang DK; Kwon YS; Kim JC; Leland PA; Kim BM; Chang SI; Raines RT
    Biochemistry; 2009 May; 48(18):3804-6. PubMed ID: 19354288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-linked trimers of bovine ribonuclease A: activity on double-stranded RNA and antitumor action.
    Gotte G; Testolin L; Costanzo C; Sorrentino S; Armato U; Libonati M
    FEBS Lett; 1997 Oct; 415(3):308-12. PubMed ID: 9357989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A ribonuclease A variant with low catalytic activity but high cytotoxicity.
    Bretscher LE; Abel RL; Raines RT
    J Biol Chem; 2000 Apr; 275(14):9893-6. PubMed ID: 10744660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandemization endows bovine pancreatic ribonuclease with cytotoxic activity.
    Leich F; Köditz J; Ulbrich-Hofman R; Arnold U
    J Mol Biol; 2006 May; 358(5):1305-13. PubMed ID: 16580680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.
    Rutkoski TJ; Raines RT
    Curr Pharm Biotechnol; 2008 Jun; 9(3):185-9. PubMed ID: 18673284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of ribonuclease cytotoxicity by a poly(amidoamine) dendrimer.
    Ellis GA; Hornung ML; Raines RT
    Bioorg Med Chem Lett; 2011 May; 21(9):2756-8. PubMed ID: 21144746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
    Chen CZ; Shapiro R
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational stability is a determinant of ribonuclease A cytotoxicity.
    Klink TA; Raines RT
    J Biol Chem; 2000 Jun; 275(23):17463-7. PubMed ID: 10747991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of ribonuclease cytotoxicity.
    Kim JS; Soucek J; Matousek J; Raines RT
    J Biol Chem; 1995 Dec; 270(52):31097-102. PubMed ID: 8537370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.